The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALKERMES PLC | COM | G01767105 | 31,523 | 1,411,682 | SH | SOLE | 1,411,682 | 0 | 0 | ||
BIOGEN INC | COM | 09062X103 | 49,301 | 184,648 | SH | SOLE | 184,648 | 0 | 0 | ||
CARDINAL HEALTH INC | COM | 14149Y108 | 22,454 | 336,742 | SH | SOLE | 336,742 | 0 | 0 | ||
EAGLE PHARMACEUTICALS INC | COM | 269796108 | 3,199 | 121,083 | SH | SOLE | 121,083 | 0 | 0 | ||
EMBECTA CORP | COM | 29082K105 | 29,487 | 1,024,200 | SH | SOLE | 1,024,200 | 0 | 0 | ||
ENANTA PHARMACEUTICALS INC | COM | 29251M106 | 30,570 | 589,360 | SH | SOLE | 589,360 | 0 | 0 | ||
EXELIXIS INC | COM | 30161Q104 | 28,561 | 1,821,475 | SH | SOLE | 1,821,475 | 0 | 0 | ||
KODIAK SCIENCES INC | COM | 50015M109 | 3,633 | 469,388 | SH | SOLE | 469,388 | 0 | 0 | ||
MCKESSON CORP | COM | 58155Q103 | 10,846 | 31,913 | SH | SOLE | 31,913 | 0 | 0 | ||
NEXTCURE INC | COM | 65343E108 | 86 | 31,298 | SH | SOLE | 31,298 | 0 | 0 | ||
REGENERON PHARMACEUTICALS | COM | 75886F107 | 41,945 | 60,889 | SH | SOLE | 60,889 | 0 | 0 | ||
TARO PHARMACEUTICAL INDUS | COM | M8737E108 | 17,412 | 580,793 | SH | SOLE | 580,793 | 0 | 0 | ||
UNITED THERAPEUTICS CORP | COM | 91307C102 | 41,961 | 200,407 | SH | SOLE | 200,407 | 0 | 0 | ||
VANDA PHARMACEUTICALS INC | COM | 921659108 | 3,086 | 312,299 | SH | SOLE | 312,299 | 0 | 0 |